Keryx Biopharmaceuticals Falls After Presentation Of Auryxia Data

Keryx Biopharmaceuticals KERX shares are trading lower by $0.16 at $6.21 in Monday's session.

At this time, investors aren't that impressed with the company's presentation of the positive real world dialysis data of Auryzia presented on Saturday. Auryxia is FDA-approved as a phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis and the company is looking to expand its usage.

See Also: Attention Biotech Investors: Here Are November PDUFA Catalysts On The Horizon

Keryx's opening print of $6.60 stands as the high for the session as of 10:45 a.m. EST. That level is just shy of its Nov. 1 high of $6.69.

Since reversing course, it surrendered all of its gains trading as low $6.11 and is now attempting to distance itself from that low.